Slc15a3和Myo1f基因在肾癌中表达的综合分析：来自RNA-seq数据和qRT-PCR验证的见解

IF 0.7 Q4 GENETICS & HEREDITY

Human Gene Pub Date : 2025-05-24 DOI:10.1016/j.humgen.2025.201422

Mahya Nazari , Seyed Abdolhamid Angaji , Behnaz Beikzadeh , Behzad Narouie , Mahdi Mohammadi

{"title":"Slc15a3和Myo1f基因在肾癌中表达的综合分析：来自RNA-seq数据和qRT-PCR验证的见解","authors":"Mahya Nazari , Seyed Abdolhamid Angaji , Behnaz Beikzadeh , Behzad Narouie , Mahdi Mohammadi","doi":"10.1016/j.humgen.2025.201422","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Early detection of renal cell carcinoma (RCC) remains a challenge. Identification of novel biomarkers may improve the diagnosis, prognosis, and treatment of RCC. This study aimed to identify potential novel biomarkers for RCC by analyzing gene expression profiles by RNA sequencing (RNA-seq) and validating the results by laboratory tests.</div></div><div><h3>Materials and methods</h3><div>Data were retrieved from NCBI GEO datasets. After data processing and analysis, two genes with differential expression in RCC were selected: Slc15a3 and Myo1f. Blood samples were then collected from 26 RCC patients and 24 healthy controls. Following the extraction of RNA and the synthesis of cDNA, real-time polymerase chain reaction (PCR) was conducted. The expression of genes was evaluated and analyzed using GraphPad Prism, with a statistical significance threshold of <em>P</em> < 0.05.</div></div><div><h3>Results</h3><div>In silico analysis and RNA-seq data revealed that Slc15a3 and Myo1f were differentially expressed in RCC. Real-time PCR results showed a significant increase in Myo1f expression in RCC patients (<em>P</em> < 0.05), suggesting its potential as a novel biomarker. However, Slc15a3 did not show significant expression differences between RCC patients and controls (<em>P</em> > 0.05), indicating a limited biomarker potential.</div></div><div><h3>Conclusion</h3><div>This study suggests that Myo1f maybe a promising biomarker for RCC.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"45 ","pages":"Article 201422"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive analysis of Slc15a3 and Myo1f gene expression in renal carcinoma: Insights from RNA-seq data and validation via qRT-PCR\",\"authors\":\"Mahya Nazari , Seyed Abdolhamid Angaji , Behnaz Beikzadeh , Behzad Narouie , Mahdi Mohammadi\",\"doi\":\"10.1016/j.humgen.2025.201422\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Early detection of renal cell carcinoma (RCC) remains a challenge. Identification of novel biomarkers may improve the diagnosis, prognosis, and treatment of RCC. This study aimed to identify potential novel biomarkers for RCC by analyzing gene expression profiles by RNA sequencing (RNA-seq) and validating the results by laboratory tests.</div></div><div><h3>Materials and methods</h3><div>Data were retrieved from NCBI GEO datasets. After data processing and analysis, two genes with differential expression in RCC were selected: Slc15a3 and Myo1f. Blood samples were then collected from 26 RCC patients and 24 healthy controls. Following the extraction of RNA and the synthesis of cDNA, real-time polymerase chain reaction (PCR) was conducted. The expression of genes was evaluated and analyzed using GraphPad Prism, with a statistical significance threshold of <em>P</em> < 0.05.</div></div><div><h3>Results</h3><div>In silico analysis and RNA-seq data revealed that Slc15a3 and Myo1f were differentially expressed in RCC. Real-time PCR results showed a significant increase in Myo1f expression in RCC patients (<em>P</em> < 0.05), suggesting its potential as a novel biomarker. However, Slc15a3 did not show significant expression differences between RCC patients and controls (<em>P</em> > 0.05), indicating a limited biomarker potential.</div></div><div><h3>Conclusion</h3><div>This study suggests that Myo1f maybe a promising biomarker for RCC.</div></div>\",\"PeriodicalId\":29686,\"journal\":{\"name\":\"Human Gene\",\"volume\":\"45 \",\"pages\":\"Article 201422\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Gene\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2773044125000488\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773044125000488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

摘要

背景肾细胞癌（RCC）的检测仍然是一个挑战。鉴定新的生物标志物可以改善肾细胞癌的诊断、预后和治疗。本研究旨在通过RNA测序（RNA-seq）分析基因表达谱，并通过实验室测试验证结果，寻找潜在的RCC新生物标志物。资料和方法数据来源于NCBI GEO数据集。经过数据处理和分析，我们选择了两个在RCC中有差异表达的基因：Slc15a3和Myo1f。然后收集了26名RCC患者和24名健康对照者的血液样本。提取RNA合成cDNA后，进行实时聚合酶链反应（PCR）。使用GraphPad Prism对基因表达进行评估和分析，P <；0.05.结果硅分析和RNA-seq数据显示，Slc15a3和Myo1f在RCC中存在差异表达。Real-time PCR结果显示，Myo1f在RCC患者中的表达显著升高(P <；0.05)，提示其作为新型生物标志物的潜力。然而，Slc15a3在RCC患者和对照组中表达差异不显著(P >；0.05)，表明生物标志物潜力有限。结论Myo1f可能是一种有前景的RCC生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comprehensive analysis of Slc15a3 and Myo1f gene expression in renal carcinoma: Insights from RNA-seq data and validation via qRT-PCR

Background

Early detection of renal cell carcinoma (RCC) remains a challenge. Identification of novel biomarkers may improve the diagnosis, prognosis, and treatment of RCC. This study aimed to identify potential novel biomarkers for RCC by analyzing gene expression profiles by RNA sequencing (RNA-seq) and validating the results by laboratory tests.

Materials and methods

Data were retrieved from NCBI GEO datasets. After data processing and analysis, two genes with differential expression in RCC were selected: Slc15a3 and Myo1f. Blood samples were then collected from 26 RCC patients and 24 healthy controls. Following the extraction of RNA and the synthesis of cDNA, real-time polymerase chain reaction (PCR) was conducted. The expression of genes was evaluated and analyzed using GraphPad Prism, with a statistical significance threshold of P < 0.05.

Results

In silico analysis and RNA-seq data revealed that Slc15a3 and Myo1f were differentially expressed in RCC. Real-time PCR results showed a significant increase in Myo1f expression in RCC patients (P < 0.05), suggesting its potential as a novel biomarker. However, Slc15a3 did not show significant expression differences between RCC patients and controls (P > 0.05), indicating a limited biomarker potential.